Pablo J. Cagnoni - Feb 1, 2023 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role
Director
Signature
/s/ Jennifer Kamocsay, attorney-in-fact
Stock symbol
RUBY
Transactions as of
Feb 1, 2023
Transactions value $
-$2,112
Form type
4
Date filed
2/1/2023, 08:41 PM
Previous filing
Jan 31, 2023
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RUBY Common Stock Sale -$2.11K -8.45K -11.34% $0.25* 66.1K Feb 1, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.